β2-Agonists and physical performance: A systematic review and meta-analysis of randomized controlled trials

Sports Medicine

Volumn 41, Issue 1, 2011, Pages 39-57

  Pluim, Babette M ^a   De Hon, Olivier ^b   Staal, J Bart ^c,d   Limpens, Jacqueline ^e,f   Kuipers, Harm ^g   Overbeek, Shelley E ^h   Zwinderman, Aeilko H ^e   Scholten, Rob J P M ^e,f  

^a The Netherlands   (Netherlands)

^b Anti Doping Authority The Netherlands   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f Dutch Cochrane Centre   (Netherlands)

^g MAASTRICHT UNIVERSITY   (Netherlands)

^h Medical Centre Alkmaar   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT;

ASTHMA; ATHLETIC PERFORMANCE; DOPING; DRUG EFFECT; EXERCISE; FEMALE; HUMAN; MALE; META ANALYSIS; METABOLISM; OXYGEN CONSUMPTION; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ASTHMA; ATHLETIC PERFORMANCE; BRONCHODILATOR AGENTS; DOPING IN SPORTS; FEMALE; HUMANS; MALE; OXYGEN CONSUMPTION; PHYSICAL EXERTION; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78650086302     PISSN: 01121642     EISSN: 11792035     Source Type: Journal    
DOI: 10.2165/11537540-000000000-00000     Document Type: Review

References (80)

1. Carlsen KH, Anderson SD, Bjermer L, et al. Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN. Allergy 2008 May; 63 (5): 492-505. (Pubitemid 351490409)
2. Larsson K, Ohlsen P, Larsson L, et al. High prevalence of asthma in cross country skiers. BMJ 1993 Nov 20; 307 (6915): 1326-9.
3. Leuppi JD, Kuhn M, Comminot C, et al. High prevalence of bronchial hyperresponsiveness and asthma in ice hockey players. Eur Respir J 1998 Jul; 12 (1): 13-6.
4. Knopfli BH, Luke-Zeitoun M, von Duvillard SP, et al. High incidence of exercise-induced bronchoconstriction in triathletes of the Swiss national team. Br J Sports Med 2007 Aug; 41 (8): 486-91.
5. Parsons JP, Kaeding C, Phillips G, et al. Prevalence of ex- ercise-induced bronchospasm in a cohort of varsity college athletes. Med Sci Sports Exerc 2007 Sep; 39 (9): 1487-92.
6. Maiolo C, Fuso L, Todaro A, et al. Prevalence of asthma and atopy in Italian Olympic athletes. Int J Sports Med 2004 Feb; 25 (2): 139-44.
7. Weiler JM, Layton T, Hunt M. Asthma in United States athletes who participated in the 1996 summer games. J Allergy Clin Immunol 1998 Nov; 102 (5): 722-6.
8. Weiler JM, Ryan 3rd EJ. Asthma in United States olympic athletes who participated in the 1998 Olympic winter games. J Allergy Clin Immunol 2000 Aug; 106 (2): 267-71.
9. Wilber RL, Rundell KW, Szmedra L, et al. Incidence of exercise-induced bronchospasm in Olympic winter sports athletes. Med Sci Sports Exerc 2000 Apr; 32 (4): 732-7
10. Rundell KW. Exercise-induced bronchospasm in the elite athlete. Sports Med 2002 Sept; 32 (9): 583-600.
11. Langdeau JB, Boulet LP. Prevalence and mechanism of de- velopment of asthma and airway hyperresponsiveness in athletes. Sports Med 2001 Aug; 31 (8): 601-16.
12. 2-Agonists at the Olympic Games. Clin Rev Allergy Immunol 2006 Oct-Dec; 31 (2-3): 259-68.
13. WADA. Medical Information to support the decisions of TUECs. Asthma. World Ant-Doping Agency, wada-ama.org [online]. Available from URL:http://www.wada-ama.org/ Documents/Science-Medicine/Medical-info-to-support- TUECs/WADA-Medical-info-Asthma-v2.3-EN.pdf [Accessed 2010 Mar 18].
14. WADA. The World Anti-Doping Code. The 2011 Pro- hibited list. World Ant-Doping Agency, wada-ama.org [online]. Available from URL:http://www.wada- ama.org/Documents/World-Anti-Doping-Program/WADP-Prohi bited-list/To-be- effective/WADA-Prohibited-List-2011- EN.pdf [Accessed 2010 Nov 14].
15. 2-agonists have an ergogenic potential in non-asthmatic competitive athletes Sports Med 2007 Feb; 37 (2): 95-102.
16. Backer V, Lund T, Pedersen L. Pharmaceutical treatment of asthma symptoms in elite athletes: doping or therapy Scand J Med Sci Sports 2007 Dec; 17 (6): 615-22.
17. Fitch KD, Sue-Chu M, Anderson SD, et al. Asthma and the elite athlete: summary of the International Olympic Committee's consensus conference, Lausanne, Switzerland, January 22-24, 2008. J Allergy Clin Immunol 2008 Aug; 122 (2): 254-60, 60 E1-7.
18. Arts FJ, Kuipers H. The relation between power output, oxygen uptake and heart rate in male athletes. Int J Sports Med 1994 Jul; 15 (5): 228-31.
19. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of Interventions version 5.0.1 [updated 2008 Sep]. The Cochrane Collaboration, 2008 [online]. Available from URL: http://www.cochrane.org/resources/ handbook/index.htm [Accessed 2009 Oct 4].
20. Review Manager (RevMan) [computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Co-chrane Collaboration, 2008.
21. Hodges AN, Lynn BM, Koehle MS, et al. Effects of inhaled bronchodilators and corticosteroids on exercise induced arterial hypoxaemia in trained male athletes. Br J Sports Med 2005 Dec; 39 (12): 917-20.
22. Caruso J, Hamill J, Yamauchi M, et al. Albuterol aids resis- tance exercise in reducing unloading-induced ankle extensor strength losses. J Appl Physiol 2005 May; 98 (5): 1705-11.
23. Caruso JF, Hamill JL, Yamauchi M, et al. Can albuterol help resistance exercise attenuate unloading-induced bone loss J Strength Cond Res 2004 Nov; 18 (4): 753-9.
24. Caruso JF, Hamill JL, Yamauchi M, et al. Albuterol and exercise effects on ankle extensor strength during 40 days of unloading. Aviat Space Environ Med 2008 Jun; 79 (6): 577-84.
25. Caruso JF, Hamill JL, Yamauchi M, et al. Albuterol helps resistance exercise attenuate unloading-induced knee extensor losses. Aviat Space Environ Med 2004 Jun; 75 (6): 505-11.
26. Caruso JF, Hamill JL, Yamauchi M, et al. Temporal strength changes from resistance exercise and albuterol on unloaded muscle. J Strength Cond Res 2008 Jul; 22 (4): 1156-63.
27. Schiffelers SL, Brouwer EM, Saris WH, et al. Inhibition of lipolysis reduces beta1-adrenoceptor-mediated thermo-genesis in man. Metabolism 1998 Dec; 47 (12): 1462-7.
28. Schiffelers SL, Saris WH, Boomsma F, et al. Beta(1)- and beta(2)-adrenoceptor-mediated thermogenesis and lipid utilization in obese and lean men. J Clin Endocrinol Metab 2001 May; 86 (5): 2191-9.
29. Suzuki J, Suzuki S, Okubo T. Effects of fenoterol on in- spiratory effort sensation and fatigue during inspiratory threshold loading. J Appl Physiol 1996 Mar; 80 (3): 727-33.
30. Amoroso P, Wilson SR, Moxham J, et al. Acute effects of inhaled salbutamol on the metabolic rate of normal subjects. Thorax 1993 Sep; 48 (9): 882-5.
31. Wilson SR, Amoroso P, Moxham J, et al. Modification of the thermogenic effect of acutely inhaled salbutamol by chronic inhalation in normal subjects. Thorax 1993 Sep; 48 (9): 886-9.
32. Lanigan C, Howes TQ, Borzone G, et al. The effects of beta 2-agonists and caffeine on respiratory and limb muscle performance. Eur Respir J 1993 Sep; 6 (8): 1192-6.
33. Musch W, Vincken W, Noppen M, et al. Metabolic effects of inhaled fenoterol in normal subjects. Chest 1992 Oct; 102 (4): 1099-103.
34. Rolett EL, Strange S, Sjogaard G, et al. Beta 2-adrenergic stimulation does not prevent potassium loss from exercising quadriceps muscle. Am J Physiol 1990 May; 258 (5 Pt 2): R1192-200.
35. Javaheri S, Smith JT, Thomas JP, et al. Albuterol has no effect on diaphragmatic fatigue in humans. Am Rev Respir Dis 1988 Jan; 137 (1): 197-201.
36. Bedi JF, Gong Jr H, Horvath SM, et al. Enhancement of exercise performance with inhaled albuterol. Can J Sport Sci 1988 Jun; 13 (2): 144-8.
37. Phillips PJ, Vedig AE, Jones PL, et al. Metabolic and cardiovascular side effects of the beta 2-adrenoceptor agonists salbutamol and rimiterol. Br J Clin Pharmacol 1980 May; 9 (5): 483-91.
38. Arlettaz A, Le Panse B, Portier H, et al. Salbutamol intake and substrate oxidation during submaximal exercise. Eur J Appl Physiol 2009 Jan; 105 (2): 207-13.
39. Decorte N, Verges S, Flore P, et al. Effects of acute salbu- tamol inhalation on quadriceps force and fatigability. Med Sci Sports Exerc 2008 Jul; 40 (7): 1220-7.
40. Sporer BC, Sheel AW, McKenzie DC. Dose response of in- haled salbutamol on exercise performance and urine concentrations. Med Sci Sports Exerc 2008 Jan; 40 (1): 149-57.
41. Tjorhom A, Riiser A, Carlsen KH. Effects of formoterol on endurance performance in athletes at an ambient temperature of -20 degrees C. Scand J Med Sci Sports 2007 Dec; 17 (6): 628-35.
42. Riiser A, Tjorhom A, Carlsen KH. The effect of formoterol inhalation on endurance performance in hypobaric conditions. Med Sci Sports Exerc 2006 Dec; 38 (12): 2132-7.
43. Van Baak MA, de Hon OM, Hartgens F, et al. Inhaled salbutamol and endurance cycling performance in non-asthmatic athletes. Int J Sports Med 2004 Oct; 25 (7): 533-8.
44. Stewart IB, Labreche JM, McKenzie DC. Acute formoterol administration has no ergogenic effect in nonasthmatic athletes. Med Sci Sports Exerc 2002 Feb; 34 (2): 213-7.
45. Goubault C, Perault MC, Leleu E, et al. Effects of inhaled salbutamol in exercising non-asthmatic athletes. Thorax 2001 Sep; 56 (9): 675-9.
46. 2-agonist formoterol upon endurance performance in healthy well-trained athletes. Respir Med 2001 Jul; 95 (7): 571-6.
47. Sue-Chu M, Sandsund M, Helgerud J, et al. Salmeterol and physical performance at -15 degrees C in highly trained nonasthmatic cross-country skiers. Scand J Med Sci Sports 1999 Feb; 9 (1): 48-52.
48. Sandsund M, Sue-Chu M, Helgerud J, et al. Effect of cold exposure (-15 degrees C) and salbutamol treatment on physical performance in elite nonasthmatic cross-country skiers. Eur J Appl Physiol Occup Physiol 1998 Mar; 77 (4): 297-304.
49. 2- agonist on physical performance at low temperature in elite athletes. Med Sci Sports Exerc 1997 Dec; 29 (12): 1631-6.
50. Carlsen KH, Ingjer F, Kirkegaard H, et al. The effect of inhaled salbutamol and salmeterol on lung function and endurance performance in healthy well-trained athletes. Scand J Med Sci Sports 1997 Jun; 7 (3): 160-5.
51. McDowell SL, Fleck SJ, Storms WW. The effects of salme- terol on power output in nonasthmatic athletes. J Allergy Clin Immunol 1997 Apr; 99 (4): 443-9.
52. Norris SR, Petersen SR, Jones RL. The effect of salbutamol on performance in endurance cyclists. Eur J Appl Physiol Occup Physiol 1996; 73 (3-4): 364-8.
53. Morton AR, Joyce K, Papalia SM, et al. Is salmeterol er- gogenic Clin J Sport Med 1996 Oct; 6 (4): 220-5.
54. Lemmer JT, Fleck SJ, Wallach JM, et al. The effects of al- buterol on power output in non-asthmatic athletes. Int J Sports Med 1995 May; 16 (4): 243-9.
55. Heir T, Stemshaug H. Salbutamol and high-intensity tread- mill running in nonasthmatic highly conditioned athletes. Scand J Med Sci Sports 1995 Aug; 5 (4): 231-6.
56. Unnithan VB, Thomson KJ, Aitchison TC, et al. Beta 2- agonists and running economy in prepubertal boys. Pediatr Pulmonol 1994 Jun; 17 (6): 378-82.
57. Fleck SJ, Lucia A, Storms WW, et al. Effects of acute in- . halation of albuterol on submaximal and maximal VO2 and blood lactate. Int J Sports Med 1993 Jul; 14 (5): 239-43.
58. Morton AR, Papalia SM, Fitch KD. Changes in anaerobic power and strength performance after inhalation of sal-butamol in nonasthmatic athletes. Clin J Sport Med 1993 Jul; 3: 14-9.
59. Signorile JF, Kaplan TA, Applegate B, et al. Effects of acute inhalation of the bronchodilator, albuterol, on power output. Med Sci Sports Exerc 1992 Jun; 24 (6): 638-42.
60. Meeuwisse WH, McKenzie DC, Hopkins SR, et al. The ef- fect of salbutamol on performance in elite nonasthmatic athletes. Med Sci Sports Exerc 1992 Oct; 24 (10): 1161-6.
61. Morton AR, Papalia SM, Fitch KD. Is salbutamol ergo- genic The effects of salbutamol on physical performance in high-performance nonasthmatic athletes. Clin J Sport Med 1992 Apr; 2 (2): 93-7.
62. Gong Jr H, Bedi JF, Horvath SM. Inhaled albuterol does not protect against ozone toxicity in nonasthmatic athletes. Arch Environ Health 1988 Jan-Feb; 43 (1): 46-53.
63. Booth M, Bogan T, Binns J. The effect of ventolin on a maximal work capacity test in trained female cyclists. NZ J Physiother 1988 Nov; 16 (3): 17-8.
64. McKenzie DC, Rhodes EC, Stirling DR, et al. Salbutamol and treadmill performance in non-atopic athletes. Med Sci Sports Exerc 1983 Jun; 15 (6): 520-2.
65. Le Panse B, Arlettaz A, Portier H, et al. Effects of acute salbutamol intake during supramaximal exercise in women. Br J Sports Med 2007 Jul; 41 (7): 430-4.
66. Le Panse B, Arlettaz A, Portier H, et al. Short term salbu- tamol ingestion and supramaximal exercise in healthy women. Br J Sports Med 2006a Jul; 40 (7): 627-31.
67. Le Panse B, Arlettaz A, Portier H, et al. Effect of chronic therapeutical b2-agonist intake during maximal exercise. Sci Sports 2006b Jun; 21 (5): 163-5.
68. Le Panse B, Collomp K, Portier H, et al. Effects of short- term salbutamol ingestion during a Wingate test. Int J Sports Med 2005 Sep; 26 (7): 518-23.
69. Collomp K, Le Panse B, Portier H, et al. Effects of acute salbutamol intake during a Wingate test. Int J Sports Med 2005 Sep; 26 (7): 513-7.
70. Caruso JF, Hamill JL, De Garmo N. Oral albuterol dosing during the latter stages of a resistance exercise program. J Strength Cond Res 2005 Feb; 19 (1): 102-7.
71. Collomp K, Candau R, Millet G, et al. Effects of salbutamol and caffeine ingestion on exercise metabolism and performance. Int J Sports Med 2002 Nov; 23 (8): 549-54.
72. Collomp K, Candau R, Collomp R, et al. Effects of acute ingestion of salbutamol during submaximal exercise. Int J Sports Med 2000a Oct; 21 (7): 480-4.
73. Collomp K, Candau R, Lasne F, et al. Effects of short-term oral salbutamol administration on exercise endurance and metabolism. J Appl Physiol 2000b Aug; 89 (2): 430-6.
74. Van Baak MA, Mayer LH, Kempinski RE, et al. Effect of salbutamol on muscle strength and endurance performance in nonasthmatic men. Med Sci Sports Exerc 2000 Jul; 32 (7): 1300-6.
75. Caruso JF, Signorile JF, Perry AC, et al. The effects of al- buterol and isokinetic exercise on the quadriceps muscle group. Med Sci Sports Exerc 1995 Nov; 27 (11): 1471-6.
76. Martineau L, Horan MA, Rothwell NJ, et al. Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci (Lond) 1992 Nov; 83 (5): 615-21.
77. Violante B, Pellegrino R, Vinay C, et al. Failure of amino- phylline and salbutamol to improve respiratory muscle function and exercise tolerance in healthy humans. Respiration 1989; 55 (4): 227-36.
78. Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiologic Reviews 1992 Jan; 14 (1): 154-76.
79. Currell K, Jeukendrup AE. Validity, reliability and sensi- tivity of measures of sporting performance. Sports Med 2008 Apr; 28 (4): 297-316.
80. Butler J, O'Brien M, O'Malley K, et al. Relationship of beta- adrenoreceptor density to fitness in athletes. Nature 1982 Jul 1; 298 (5869): 60-2